Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Read more about Astellas Announces Acquisition of Own Shares
Tokyo and Mainz, October 28, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a...
Read more about Astellas Announces Acquisition of Own Shares
TOKYO and NEW YORK, Oct. 21, 2016 -- Astellas Pharma Inc. (TSE: 4503) and Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug...
Tokyo, October 20, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announces that it will launch the newest element in its global corporate brand campaign...
Tokyo, October 19, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that Astellas has terminated the discussion with the...
Read more about Termination of Business Transfer Discussion with Kaketsuken
MONTREAL and TOKYO, 14 October 2016 – The World Anti-Doping Agency (President: Sir Craig Reedie, “WADA”) and Astellas Pharma Inc. (TSE: 4503: President and CEO: Yoshihiko Hatanaka,...
North Brunswick, N.J. and Tokyo, October, 12, 2016 – Chromocell Corporation and Astellas Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
NORTHBROOK, Ill., October 11, 2016 – Astellas Oncology announced the three winners of the inaugural C3 Prize – a global challenge designed to acknowledge non-medicine innovations to improve...
Follow us
